NCT01430260View on ClinicalTrials.gov

Omnaris Versus Levocetirizine Phase 4 Study

PHASE4CompletedINTERVENTIONAL

Enrollment

349

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Allergic Rhinitis

Interventions

DRUG

Ciclesonide

200 ㎍ once daily

DRUG

Levocetirizine

5mg once daily

DRUG

Ciclesonide & Levocetirizine

"* Omnaris (ciclesonide) 200 ㎍ once daily~* Levocetirizine 5mg once daily"

Trial Locations (1)

135-755

handok pharmaceuticals co. LTD, Seoul

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Takeda

INDUSTRY

lead

Handok Inc.

INDUSTRY

NCT01430260 - Omnaris Versus Levocetirizine Phase 4 Study | Biotech Hunter | Biotech Hunter